This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Google Healthcare Startup Calico Partners With Abbvie

09/03/14 - 01:19 PM EDT

Google Healthcare Startup Calico Partners With Abbvie Under the agreement, Calico and Abbvie will work together to discover and develop new drugs for age-related diseases, including neuro-degeneration and cancer.

READ FULL POST

Sunesis Takes a Run Through the Feuerstein-Ratain Rule

09/02/14 - 10:29 AM EDT

Sunesis Takes a Run Through the Feuerstein-Ratain Rule Results from Sunesis' phase III study in acute myeloid leukemia should be released this month or next.

READ FULL POST

Biotech Stock Boom Times Are Back

08/26/14 - 07:00 AM EDT

Biotech Stock Boom Times Are Back The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

READ FULL POST

Galena Fires CEO Ahn, Offers No Parting Gifts

08/25/14 - 08:48 AM EDT

Galena Fires CEO Ahn, Offers No Parting Gifts CEOs who leave companies on good terms get cushy severance packages. Galena's Ahn did not.

READ FULL POST

Ampio: The Freezer Killed My Osteoarthritis Drug

08/21/14 - 10:23 AM EDT

Ampio: The Freezer Killed My Osteoarthritis Drug Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.

READ FULL POST

Northwest Bio Can't Keep Its DC-Vax Claims Straight

08/14/14 - 10:20 AM EDT

Northwest Bio Can't Keep Its DC-Vax Claims Straight Contradictory statements made on whether or not Northwest Bio conducted an interim analysis of its DC-Vax phase III study.

READ FULL POST

Blame MannKind's Fall on its Bloated Balance Sheet

08/13/14 - 12:04 PM EDT

Blame MannKind's Fall on its Bloated Balance Sheet Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.

READ FULL POST

Arrowhead Discloses First Human Hepatitis B Therapy Results

08/12/14 - 05:11 PM EDT

Arrowhead Discloses First Human Hepatitis B Therapy Results The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.

READ FULL POST

Dendreon Warns Debt Bomb Might Wipe Out Shareholders

08/12/14 - 07:17 AM EDT

Dendreon Warns Debt Bomb Might Wipe Out Shareholders The struggling Provenge peddler is suffocating under $620 million in debt and the bill comes soon.

READ FULL POST

Intercept Pharma Shares Higher on Positive Fatty Liver Drug Data

08/11/14 - 05:29 PM EDT

Intercept Pharma Shares Higher on Positive Fatty Liver Drug Data Intercept's OCA data look good. I don't see anything in the study results which scream, "RUN AWAY!" This is what some investors feared, causing the stock price to fall recently.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

Chart of I:DJI
DOW 16,560.30 -94.47 -0.57%
S&P 500 1,980.22 -7.44 -0.37%
NASDAQ 4,806.6160 -6.0920 -0.13%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs